What is ACT Genomics Taiwan?
ACT Genomics operates at the intersection of tumor biology, bioinformatics, and clinical oncology. The firm provides a comprehensive suite of precision medicine services designed to navigate the complexities of cancer treatment. Their core offerings include detailed genomic profiling, which assists clinicians in identifying targeted therapies, monitoring for potential relapse, and evaluating the efficacy of immunotherapy. By integrating advanced sequencing technologies with proprietary analytical frameworks, ACT Genomics serves as a critical partner for healthcare providers seeking to optimize treatment protocols for patients with drug-resistant or advanced-stage malignancies. Their market position is defined by a commitment to evidence-based medicine and a robust operational footprint that spans the most dynamic healthcare ecosystems in the Asia-Pacific region.
How much funding has ACT Genomics Taiwan raised?
ACT Genomics Taiwan has raised a total of $20.5M across 2 funding rounds:
Series A
$8M
Series B
$12.5M
Series A (2015): $8M, investors not publicly disclosed
Series B (2016): $12.5M led by President International Development and UMC Capital
Key Investors in ACT Genomics Taiwan
President International Development
President International Development Corporation serves as the primary investment arm for the Uni-President Group, focusing on large-scale strategic projects across diverse sectors including finance and international trade.
UMC Capital
UMC Capital is the investment division of a global semiconductor foundry leader, providing strategic support to high-tech ventures that leverage advanced engineering and data-intensive technologies.
What's next for ACT Genomics Taiwan?
With the recent capital deployment, ACT Genomics is well-positioned to accelerate its research and development initiatives, particularly in the realm of liquid biopsy and real-time cancer monitoring. The company is expected to focus on expanding its bioinformatics capabilities to handle increasingly large datasets, thereby enhancing the accuracy of its risk assessment models. Furthermore, the strategic backing from institutional investors suggests a long-term commitment to scaling their precision medicine platform, likely involving deeper integration with regional hospital networks and pharmaceutical partners. As the industry shifts toward personalized therapeutic interventions, ACT Genomics remains a frontrunner in translating genomic insights into improved patient survival rates and more efficient clinical workflows.
See full ACT Genomics Taiwan company page
